Ftc Sues Pharma Data Giant Iqvia To Block Purchase And Potential The proposed transaction and the subsequent challenge by the ftc come after iqvia's acquisition of lasso marketing, another pharma and healthcare ad technology company, for $445 million last year. On july 17, 2023, the federal trade commission sued to block iqvia holdings inc. (iqvia) from acquiring propel media, inc. (pmi), alleging in an administrative complaint that the proposed acquisition would give iqvia a market leading position in programmatic advertising for health care products, namely prescription drugs, to doctors and other health care professionals.
Will The Ftc Rein In Iqvia S Health Data Empire The ftc is seeking a temporary restraining order and preliminary injunction in federal court to stop the sale, authorized by a commission vote of 3 0. iqvia is the largest global health care data provider and sources its vast stores of information from more than 550 suppliers and almost 100 pharma manufacturers, according to its website. The ftc filed to block the purchase in july 2023, saying that iqvia, "the world’s largest health care data provider," acquiring propel media "would give iqvia a market leading position in. The ftc originally sued to block the acquisition in july 2023. according to a press release from the ftc, “…the proposed acquisition would give iqvia a market leading position in programmatic advertising for health care products, namely prescription drugs, to doctors and other health care professionals.”. A us court has upheld the federal trade commission’s (ftc) order to prevent the acquisition of deepintent, a healthcare advertising firm, by iqvia, a u.s. headquartered healthcare data and.
Iqvia Pharma Deals Half Year Review Of 2024 Iqvia The ftc originally sued to block the acquisition in july 2023. according to a press release from the ftc, “…the proposed acquisition would give iqvia a market leading position in programmatic advertising for health care products, namely prescription drugs, to doctors and other health care professionals.”. A us court has upheld the federal trade commission’s (ftc) order to prevent the acquisition of deepintent, a healthcare advertising firm, by iqvia, a u.s. headquartered healthcare data and. The ftc filed a lawsuit on monday to block iqvia from buying adtech firm propel media. the agency is moving to stop the sale to prevent the consolidation of programmatic. Feds turn antitrust focus to digital pharma ads the investigation into health data giant iqvia’s ad tech deal focuses on harm to rivals and increased costs for drugmakers.
Ftc Targets Digital Pharma Ads The ftc filed a lawsuit on monday to block iqvia from buying adtech firm propel media. the agency is moving to stop the sale to prevent the consolidation of programmatic. Feds turn antitrust focus to digital pharma ads the investigation into health data giant iqvia’s ad tech deal focuses on harm to rivals and increased costs for drugmakers.
Iqvia Responds To Ftc S Block On Acquisition Of Propel Media